[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652048":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Pyrotech Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PTT-121 treatment","EXPERIMENTAL",null,[13],"Drug: PTT-121",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo treatment","PLACEBO_COMPARATOR",[18],"Drug: PTT-121 placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","PTT-121","PTT-121 will be administered intravenously",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"PTT-121 placebo","Matching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Ran Wei","CONTACT","+86 10 81938094","ran.wei@pyrotech.com",[36],{"facility":37,"status":11,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Peking University Third Hospital","Beijing","Beijing Municipality","100089","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":11,"email":53},"Xue Hong","+86 10 82265573","bysyec@163.comhaiyanli1027@hotmail.com",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100652048","phase-1-a-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-ptt-121-100652048",false,"NCT07768176","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121","A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PTT-121 After Single and Multiple Ascending Doses in Healthy Chinese Subjects","Inclusion Criteria:\n\n* Healthy adults aged between 18 and 55 years.\n* BMI 18.0-26.0.\n* Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination, etc.\n\nExclusion Criteria:\n\n* History of any clinically significant disease or disorder of the cardiovascular, respiratory, gastrointestinal, genitourinary, hematologic\u002Flymphatic, neurologic, reproductive, psychiatric, endocrine, immunologic, musculoskeletal, breast, ear, ocular, thyroid, neoplastic, metabolic, or dermatologic systems, as determined by the Investigator.\n* History of hypersensitivity to the active ingredient of the investigational product, any of its excipients, or related compounds; or a history of severe drug-induced allergic reactions, including but not limited to angioedema and bronchospasm\u002Fasthma.",true,"ALL","18 Years","55 Years",{"count":68,"type":69},84,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1","This is a Phase I, single-center, randomized, double-blind, placebo-controlled SAD\u002FMAD study to evaluate safety, tolerability, and PK of Intravenously Administered PTT-121 in healthy Chinese adults.",[75],"Healthy Vollunteer","NOT_YET_RECRUITING","2026-08-13",{"date":79,"type":80},"2026-08-17","ACTUAL",{"date":82,"type":69},"2026-08-31",{"date":84,"type":69},"2028-02-28",{"name":5,"class":6},1]